Steve, BPs enter into licensing deals for products at all stages of development. Look at Amgen for pre-clinical NEO. The fact that AXAL is up for EMA approval is a big plus for a BP. However, the price also goes up. I’m sure that the price has been the sticking point thus far. Good. Don’t give it away cheap.
News 
Market Data 
Discover 
AI
